Evonik is investing in the short-term expansion of its specialty lipids production which are essential for mRNA-based COVID-19 vaccines. Commercial lipid quantities are to be produced at Evonik’s Hanau and Dossenheim sites in Germany as early as the second half of 2021 as part of a strategic partnership with vaccine manufacturer BioNTech. This step contributes to increasing the supply security of the Pfizer-BioNTech COVID-19 vaccine.   “The pandemic requires decisive action,” said Ch...